More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/BMS-309403 [300657-03-8]
Chemical Structure
Chemical Structure
Chemical Structure

BMS-309403 [300657-03-8]

Research Use Only
AG-CR1-3640
AdipoGen Life Sciences
CAS Number300657-03-8
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight474.6
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    BMS-309403 [300657-03-8]
  • Delivery Days Customer
    10
  • CAS Number
    300657-03-8
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C31H26N2O3
  • Molecular Weight
    474.6
  • Scientific Description
    Cell permeable, potent and selective fatty acid binding protein 4 (FABP4; A-FABP; ALBP; adipocyteP2 protein) inhibitor that competitively targets the fatty acid-binding pocket (Ki= <2nM). Inhibits FABP3 (muscle) and FABP5 (epidermal) with lower affinity (Ki=250nM and 350nM, respectively). FABP4 is an intracellular lipid-binding protein responsible for the transportation of fatty acids. It is expressed primarily in adipose tissue and is associated with inflammation, obesity, diabetes and cardiovascular diseases. Glucose uptake stimulator. Reduces blood glucose levels and increases insulin sensitivity in a mouse model of obesity. Protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. Anti-atherosclerotic. Decreases fatty acid uptake in adipocytes in vitro and reduces atherosclerotic lesion area in a mouse model of atherosclerosis. - Chemical. CAS: 300657-03-8. Formula: C31H26N2O3. MW: 474.6. Cell permeable, potent and selective fatty acid binding protein 4 (FABP4; A-FABP; ALBP; adipocyteP2 protein) inhibitor that competitively targets the fatty acid-binding pocket (Ki= <2nM). Inhibits FABP3 (muscle) and FABP5 (epidermal) with lower affinity (Ki=250nM and 350nM, respectively). FABP4 is an intracellular lipid-binding protein responsible for the transportation of fatty acids. It is expressed primarily in adipose tissue and is associated with inflammation, obesity, diabetes and cardiovascular diseases. Glucose uptake stimulator. Reduces blood glucose levels and increases insulin sensitivity in a mouse model of obesity. Protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. Anti-atherosclerotic. Decreases fatty acid uptake in adipocytes in vitro and reduces atherosclerotic lesion area in a mouse model of atherosclerosis.
  • SMILES
    CCC1=C(C2=CC=CC=C2)C(C3=CC=CC=C3)=NN1C4=CC=CC=C4C5=CC(OCC(O)=O)=CC=C5
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP): R. Sulsky, et al.; Bioorg. Med. Chem. Lett. 17, 3511 (2007)
  • Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2: M. Furuhashi, et al.; Nature 447, 959 (2007)
  • BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase: W. Lin, et al.; PLoS One 7, e44570 (2012)
  • FABP4 attenuates PPARgamma and adipogenesis and is inversely correlated with PPARgamma in adipose tissues: T. Garin-Shkolnik, et al.; Diabetes 63, 900 (2014)
  • FABP4 inhibition suppresses PPARgamma activity and VLDL-induced foam cell formation in IL-4-polarized human macrophages: M. Boss, et al.; Atherosclerosis 240, 424 (2015)